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sayed by immunoblotting, were present in all patients with AA. The 
antibodies were predominantly directed to one or more antigens of 
approximately 48-50, 52-54, 58-60, and 62-64 kD. Antibodies to 
the 58-60-kD and the 52-54-kD antigens were present in 80% and 
86%, respectively of 49 patients with AA but in only 14% and 27% of 
22 control individuals. These diJferences were statistically significant. 
These antigens were expressed by keratinocytes derived from HF but 
could not be detected on keratinocytes derived from epidermis, 
indicating that keratinocytes in these two diJferent locations are 
antigenically diJferent. The incidence and level of HF keratinocyte 
antibodies correlated with disease severity. Patients with more severe 
disease (i.e., A. tota/is and A. universa/is) had a significantly higher 
incidence of antibodies to the 62-64-, 58-60-, and 48-50-kD HF 
keratinocyte antigens than patients with less severe patchy AA. 
Preliminary results also suggest AA antibodies react to HF 
melanocytes. By indirect immunofluorescence, IgG antibodies to 
cytoplasmic antigens in fixed HF melanocytes were present in most 
AA patients (82%) but in only 10% of controls. The identity and 
specificity of the HF melanocytes antigens defined by AA antibod­
ies is currently under investigation. 
THE JOURNAL OF INVESTIGATIVE DERMATOLOGY 
These results indicate that HF express unique antigens not 
found in adjacent scalp tissue, and that abnormal circulating 
antibodies to some HF-specific antigens are present in individ­
uals with AA. This provides the first direct evidence that 
abnormal immune responses specifically directed to antigens 
expressed only in HF are associated with AA. These findings 
strongly support the hypothesis that AA results from abnormal 
autoimmune responses to HF and can provide an explanation for 
the selective damage to HF that occurs in this disease. 
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T he events that induce premature telogen or dystro­phic anagen growth patterns in alopecia areata (AA) are so far not understood. Although the nature of the noxious signal is still unknown, it has been assumed that CD4 +T lymphocytes might trigger the hair loss 
[1]. These T lymphocytes invade the hair follicles and apparently 
interact with the hair-follicle cells. Such interaction may occur 
either by direct cell-to-cell contact and cytotoxicity, or indirectly 
by lymphokines that might affect the differentiation and growth of 
follicular epithelial cells. Because the T lymphocytes obviously do 
not promote cytotoxic activity we hypothesize that AA is triggered 
by soluble mediators that "switch off" the hair cycle, resulting in 
hair loss. The presence of such mediators (e.g., interferon [IFN]-,)" 
tumor necrosis factor [TNF]-O') would explain the increased adhe­
sion molecule expression on affected hair follicles and the non­
destructive nature of the disease. 
At present, topical immunotherapy with a potent contact allergen 
such as diphenylcyclopropenone (DCP) appears to be superior to 
other modes of treatment [2]. Why an allergic contact dermatitis is 
able to reverse the pathogenic process and induce hair regrowth is 
still unknown. If it is true that AA results from a distinct cytokine 
pattern, we can infer that the beneficial effect of DCP should be 
mediated by cytokines locally released during the contact allergy. 
To address this question we performed a semiquantitative reverse­
transcriptase polymerase chain reaction [3] with RNA extracted 
from scalp biopsies that were obtained from patients with AA 
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before and after successful treatment with DCP, and from healthy 
controls. We detected a T-cell response with increased steady-state 
mRNA levels for IFN-,)" interleukin (IL)-l{3 and IL-2 in untreated 
AA of the totalis type. Mter DCP treatment we found increased 
mRNA steady-state levels for IL-2, IL-8, IL-l0, and TNF-O'. No 
transcripts for IL-4 were found, whereas IL-6 mRNA expression 
was low. IFN-')' and IL-l{3 transcripts were increased as compared 
to controls but, when compared to untreated AA, the overall 
expression level was reduced by 60% and 15% for IFN-')' and IL-l{3, 
respectively. 
With our results we provide experimental evidence that cyto­
kines participate in the pathogenesis of AA. We detected increased 
lesional levels ofIFN-,)" IL-2, and IL-l{3 transcripts in scalp biopsies 
from patients with untreated AA, corresponding to a cytokine 
pattern of the Thl T -helper type. As IFN-')' is known to be crucially 
involved in adhesion molecule expression on hair follicles, our 
fmdings offer an explanation for the aberrant expression of mole­
cules such as ICAM-l and HLA-DR on affected hair follicles. 
Furthermore, IL-l{3 has been shown to inhibit hair growth ill vitro 
[4] , and our results suggest that IL-l {3 may trigger the harr growth 
arrest even ill vivo. 
The pathways by which DCP therapy induces hair regrowth are 
unknown. However, we assume a substantial action of IL-l0. IL-10 
has been characterized by its ability to inhibit Thl cytokine 
production. Several lines of evidence, however, indicate a more 
pleiotropic function of IL-l 0 as a modulator of immune responses 
[ 5]. If we assume that IL-l0 is involved in the induction of hair 
regrowth by DCP therapy, this hypothesis would explain the 
decreased expression of ICAM-l and HLA-DR molecules on 
hair-follicle keratinocytes. This hypothesis is supported by the 
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observation that irritants, which do not induce IL-10 expression, 
are not effective in AA, whereas contact allergens such as DCP are 
[6]. On the other hand, phototherapy may be beneficial in AA. 
Ultraviolet light has been shown to be a potent inducer of IL-10 
expression in keratinocytes. Theoretically, intralesional application 
of recombinant IL-10 should provide a novel therapeu tic approach 
for AA . This approach would be more specific than application of 
a potent contact allergen. 
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A lopecia areata is a common inflammatory disorder affecting the hair and, in some cases, the nails. There is a strong hereditary component with a positive family history ranging from 10% to 25% in different studies, although the true figure may be higher, as 
mild cases are often overlooked. Associations with several major 
histocompatibility complex loci have been reported including 
DR-4 and DQW-7. 
We have been investigating the question "why do some patients 
develop one patch of alopecia areata that regrows without further 
episodes, whereas others develop alopecia totalis or universalis for 
the rest of their lives?" Perhaps the answer lies in genes that 
determine severity rather than susceptibility to alopecia areata. 
One of the major determinants of an inflammatory response in 
the skin is the local production of pro-inflammatory cytokines and 
their antagonists, in particular, interleukin-1 (IL-1) and the IL-1 
receptor antagonist (IL-lra). If an individual produces high 
levels of pro-inflammatory cytokines and/or low levels of 
cytokine inhibitor , this would result in the amplification and 
perpetuation of an inflammatory response to any stimulus. We 
postulated that polymorphisms within cytokine and related 
genes may be associated with alopecia areata and other inflam­
matory skin diseases. These polymorphisms could result in 
differences in cytokine/ cytokine inhibitor production that would 
favor the inflammatory response. 
There are very high levels of interleukin-l a (IL-l a) seques­
tered inside normal keratinocytes that can be released following 
trauma, ultraviolet B irradiation and local infection. We have 
previously demonstrated that there are decreased levels of the 
endogenous antagonist to IL-1, the IL-l receptor antagonist 
(IL-1ra) in other inflammatory skin diseases including psoriatic 
plaques. IL-1a inhibits human hair-follicle growth and hair-fiber 
production in whole organ cultures [1]. IL-1 may therefore play 
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a role in alopecia areata through a direct growth-inhibitory effect 
on hair follicles. The gene for IL-1ra (IL-1rn) is located on the 
long arm of chromosome 2 on a 430-kb stretch of DNA that also 
contains the genes for IL-1a and IL-1{3. 
We have described a variable number tandem repeat poly­
morphism (VNTR) in intron 2 of the IL-1 ra gene. Eve alleles 
of the system were identified corresponding to two, three, four, 
five, and six copies of an 86 -base pair repeat sequence. We have 
tested the genetic association of alopecia areata with this IL-1ra 
polymorphism by comparing the allele frequencies in patients 
with alopecia areata and healthy individuals in a case-control 
association study. 
MATERIALS AND METHODS 
Blood was collected from 261 unrelated, healthy Caucasian individuals from 
the North of England population and from 90 alopecia arcata patients 
attending the dermatology out-patient clinic at the Royal Hallamshire 
Hospital in Sheffield. Prior to genetic analysis, the patients were divided into 
three groups : patchy alopecia, alopecia totalis, and alopecia universalis. 
DNA was extracted using standard methods. 
Polymorphism typing was based on a PCR method as previously de­
scribed [2]. The rate of gene carriage (i.e., the number of individuals 
carrying at least one copy of a specific allele as a proportion of the total 
number of individuals) was calculated. 
RESULTS 
The carriage of allele 2 of the interleukin-1 receptor antagonist 
gene is shown in Fig 1. This was 41 % in the general population 
compared with 44% in patients with patchy alopecia areata, 66% in 
patients with alopecia totalis, and 77% in alopecia universalis (p 
0.005, OR = 5). 
DISCUSSION 
Alopecia areata seems to be a polygenic disease with genetic 
susceptibility and severity factors. Genetic factors probably interact 
with environmental factors such as infection to trigger the disease. 
The severity of an inflammatory response to an environmental 
trigger may be determined by the balance of pro-inflammatory 
(e.g., IL-la, IL-1(3) and anti-inflammatory cytokines and/or cyto-
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